{"transactions":[{"id":1680727,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-11T22:04:56.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":2812,"price":16.3281,"value":45914.6172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":205605,"source":{"system":"sec-edgar","filing":"0000950170-24-003974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024003974/ownership.xml","form_type":"4"}},{"id":1889036,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-17T20:58:42.000Z","date":"2023-05-15","kind":"exercise","planned":true,"acquired":false,"shares":9764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023."}],"balance_after":33770,"derivative":{"exercise_price":6.88,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":9764},"source":{"system":"sec-edgar","filing":"0000950170-23-022775","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023022775/ownership.xml","form_type":"4"}},{"id":1889035,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-17T20:58:42.000Z","date":"2023-05-15","kind":"exercise","planned":true,"acquired":false,"shares":2201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023."}],"balance_after":15404,"derivative":{"exercise_price":0.37,"expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":2201},"source":{"system":"sec-edgar","filing":"0000950170-23-022775","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023022775/ownership.xml","form_type":"4"}},{"id":1889034,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-17T20:58:42.000Z","date":"2023-05-15","kind":"sale","planned":true,"acquired":false,"shares":11965,"price":29.0312,"value":347358.308,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":208417,"source":{"system":"sec-edgar","filing":"0000950170-23-022775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023022775/ownership.xml","form_type":"4"}},{"id":1889033,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-17T20:58:42.000Z","date":"2023-05-15","kind":"exercise","planned":true,"acquired":true,"shares":9764,"price":6.88,"value":67176.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."}],"balance_after":220382,"source":{"system":"sec-edgar","filing":"0000950170-23-022775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023022775/ownership.xml","form_type":"4"}},{"id":1889032,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-17T20:58:42.000Z","date":"2023-05-15","kind":"exercise","planned":true,"acquired":true,"shares":2201,"price":0.37,"value":814.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."}],"balance_after":210618,"source":{"system":"sec-edgar","filing":"0000950170-23-022775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023022775/ownership.xml","form_type":"4"}},{"id":1917212,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-19T23:45:13.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":false,"shares":4718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the date of this filing, 18,464 shares subject to the option are vested and exercisable. 29,788 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023."}],"balance_after":43534,"derivative":{"exercise_price":6.88,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":4718},"source":{"system":"sec-edgar","filing":"0000899243-23-011461","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011461/doc4.xml","form_type":"4"}},{"id":1917211,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-19T23:45:13.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":false,"shares":44861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the date of this filing, 44,861 shares subject to the option are vested and exercisable. 17,605 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023."}],"balance_after":17605,"derivative":{"exercise_price":0.37,"expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":44861},"source":{"system":"sec-edgar","filing":"0000899243-23-011461","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011461/doc4.xml","form_type":"4"}},{"id":1917210,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-19T23:45:13.000Z","date":"2023-04-17","kind":"sale","planned":true,"acquired":false,"shares":300,"price":30.94,"value":9282.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."}],"balance_after":208417,"source":{"system":"sec-edgar","filing":"0000899243-23-011461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011461/doc4.xml","form_type":"4"}},{"id":1917209,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-19T23:45:13.000Z","date":"2023-04-17","kind":"sale","planned":true,"acquired":false,"shares":49279,"price":30.5335,"value":1504660.3465,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":208717,"source":{"system":"sec-edgar","filing":"0000899243-23-011461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011461/doc4.xml","form_type":"4"}},{"id":1917208,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-19T23:45:13.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":true,"shares":4718,"price":6.88,"value":32459.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."}],"balance_after":257996,"source":{"system":"sec-edgar","filing":"0000899243-23-011461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011461/doc4.xml","form_type":"4"}},{"id":1917207,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-19T23:45:13.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":true,"shares":44861,"price":0.37,"value":16598.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."}],"balance_after":253278,"source":{"system":"sec-edgar","filing":"0000899243-23-011461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011461/doc4.xml","form_type":"4"}},{"id":1939106,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":false,"shares":16748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter."}],"balance_after":48252,"derivative":{"exercise_price":6.88,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":16748},"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939105,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":false,"shares":30041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023."}],"balance_after":62466,"derivative":{"exercise_price":0.37,"expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":30041},"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939104,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":false,"shares":2789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to such option are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.33,"expiration_date":"2028-02-16","underlying":"Common Stock","underlying_shares":2789},"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939103,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":41250,"derivative":{"exercise_price":32.08,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939102,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":9167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":208417,"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939101,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":2416,"price":32.4331,"value":78358.3696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":199250,"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939100,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":52211,"price":31.8485,"value":1662842.0335,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":201666,"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939099,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":16748,"price":6.88,"value":115226.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":253877,"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939098,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":30041,"price":0.37,"value":11115.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":237129,"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939097,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:45:03.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":2789,"price":0.33,"value":920.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":207088,"source":{"system":"sec-edgar","filing":"0000899243-23-009600","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009600/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1944501,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-21T00:25:55.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":41250,"derivative":{"exercise_price":32.08,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000899243-23-009178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009178/doc4.xml","form_type":"4"}},{"id":1944500,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:25:55.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":9167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":158839,"source":{"system":"sec-edgar","filing":"0000899243-23-009178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009178/doc4.xml","form_type":"4"}},{"id":1944499,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:25:55.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":2416,"price":32.4331,"value":78358.3696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":149672,"source":{"system":"sec-edgar","filing":"0000899243-23-009178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009178/doc4.xml","form_type":"4"}},{"id":1944498,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:25:55.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":52211,"price":31.8485,"value":1662842.0335,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":152088,"source":{"system":"sec-edgar","filing":"0000899243-23-009178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009178/doc4.xml","form_type":"4"}},{"id":2057547,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-11T00:22:45.000Z","date":"2023-01-06","kind":"sale","acquired":true,"shares":629,"price":36.7888,"value":23140.1552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":204299,"source":{"system":"sec-edgar","filing":"0000899243-23-001526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323001526/doc4.xml","form_type":"4"}},{"id":2057546,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-11T00:22:45.000Z","date":"2023-01-06","kind":"sale","acquired":true,"shares":1405,"price":36.0789,"value":50690.8545,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":204928,"source":{"system":"sec-edgar","filing":"0000899243-23-001526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323001526/doc4.xml","form_type":"4"}},{"id":2438913,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-11T01:34:26.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":127500,"derivative":{"exercise_price":19,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0000899243-22-001522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001522/doc4.xml","form_type":"4"}},{"id":2438912,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":95252,"kind":"person","name":"Yeramian Patrick D","position":1,"cik":"0001358266","reported_name":"Yeramian Patrick D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-11T01:34:26.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":28333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":206333,"source":{"system":"sec-edgar","filing":"0000899243-22-001522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001522/doc4.xml","form_type":"4"}}]}